We are live on ! Find out more
PDSB icon

PDS Biotechnology

52 hedge funds and large institutions have $6.94M invested in PDS Biotechnology in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,108% more call options, than puts

Call options by funds: $157K | Put options by funds: $13K

21% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 14

0.42% less ownership

Funds ownership: 11.79%11.37% (-0.42%)

9% less funds holding

Funds holding: 5752 (-5)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

58% less capital invested

Capital invested by funds: $16.6M → $6.94M (-$9.64M)

Holders
52
Holders Change
-5
Holders Change %
-8.77%
% of All Funds
0.68%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
17
Reduced
14
Closed
12
Calls
$157K
Puts
$13K
Net Calls
+$144K
Net Calls Change
-$928K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.45M -$41.6K -15,731 -1%
BlackRock
2
BlackRock
New York
$853K +$92.2K +34,846 +7%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$680K +$5.57K +2,104 +0.5%
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$403K +$298K +112,717 +84%
Citadel Advisors
5
Citadel Advisors
Florida
$359K +$279K +105,233 +92%
William Blair & Company
6
William Blair & Company
Illinois
$257K +$94.6K +35,757 +29%
State Street
7
State Street
Massachusetts
$217K +$56.9K +21,500 +19%
Millennium Management
8
Millennium Management
New York
$206K -$285K -107,793 -46%
Renaissance Technologies
9
Renaissance Technologies
New York
$163K +$203K +76,800 +331%
Northern Trust
10
Northern Trust
Illinois
$135K -$27.2K -10,261 -11%
Commonwealth Equity Services
11
Commonwealth Equity Services
Massachusetts
$127K -$1.78K -672 -0.9%
IWA
12
Inspirion Wealth Advisors
Illinois
$124K -$717K -270,862 -79%
Two Sigma Investments
13
Two Sigma Investments
New York
$107K +$127K +48,132 +273%
VF
14
Virtu Financial
New York
$89K +$145K +54,693 New
UBS Group
15
UBS Group
Switzerland
$81.6K +$78.9K +29,824 +147%
Vontobel Holding
16
Vontobel Holding
Switzerland
$65.2K
Marshall Wace
17
Marshall Wace
United Kingdom
$63.6K +$28.7K +10,837 +38%
Jane Street
18
Jane Street
New York
$58.1K +$94.3K +35,644 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$47.8K
Bank of America
20
Bank of America
North Carolina
$43.9K -$34 -13 -0%
T. Rowe Price Associates
21
T. Rowe Price Associates
Maryland
$41K
XT
22
XTX Topco
Cayman Islands
$40K -$113K -42,647 -63%
TWP
23
Tempus Wealth Planning
California
$30.6K
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$30K -$18.3K -6,908 -27%
Morgan Stanley
25
Morgan Stanley
New York
$29.2K -$25.2K -9,538 -35%

PDSB Hedge Fund Activity: Q4 2024 in Review

52 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2024, worth a combined $6.94M — down 58% from $16.6M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of PDSB and 8 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 17 added.

The largest buyer was Susquehanna International Group, adding an estimated $298K. The largest seller was Inspirion Wealth Advisors, cutting an estimated $717K.

  • 52 institutional investors held PDS Biotechnology (PDSB) as of Q4 2024, down from 57 in Q3 2024.
  • Funds reported $6.94M of PDS Biotechnology stock for Q4 2024, down 58% quarter-over-quarter.
  • 8 funds opened new PDS Biotechnology positions in Q4 2024 and 12 closed out, a net change of -4 holders.
  • The largest PDS Biotechnology buyer in Q4 2024 was Susquehanna International Group, an estimated $298K added.
  • The largest PDS Biotechnology seller in Q4 2024 was Inspirion Wealth Advisors, an estimated $717K sold.

Based on aggregated 13F filings for Q4 2024.